Startups
2016
METABOSTEM SLThe metabostemness hallmark provides a unique framework to discover & develop innovative drugs aimed at re-writing or uninstalling the metabolic operating system of CSCs.
Company ceased activity
Company ceased activity
Address
Carrer de Calàbria 241, 08029 Barcelona, Spain
CERCA ownership
CERCA Center Contact
AV
Status & Deeptech areas
Company Status & Company Deeptech AreasCurrent company status
DeepTech Area
Spinoff information
Company Description
METABOSTEM is a Barcelona-based Biopharmaceutical Company passionately committed to transforming the lives of cancer patients by entering a new dimension of precision medicine. The pioneering science behind METABOSTEM has the goal of developing breakthrough oncology drugs directed to the unique metabolic features of cancer stem cells (CSCs), the most dangerous & deadliest type of cancer cell. The Company is a spinout of the Catalan Institute of Oncology.
Product description
MS-001: A FIRST-IN-CLASS, DUAL-ACTION METABOLO-EPIGENETIC DRUG
The Company is currently in the late preclinical testing stages and early formulation development of its most advanced chemical lead candidate, MS-001. MS-001 is a first-in-class, dual-action metabolo-epigenetic drug. Using METABOSTEM’s scientific knowledge of the metabostemness cancer hallmark, METABOSTEM identified MS-001 as a valuable drug candidate for eradicating CSCs. Research on MS-001 included a systematic analysis of the anti-CSC activity on in vitro and in vivo human-derived models of biologically aggressive, CSC-enriched types of human carcinomas.
The Company is currently in the late preclinical testing stages and early formulation development of its most advanced chemical lead candidate, MS-001. MS-001 is a first-in-class, dual-action metabolo-epigenetic drug. Using METABOSTEM’s scientific knowledge of the metabostemness cancer hallmark, METABOSTEM identified MS-001 as a valuable drug candidate for eradicating CSCs. Research on MS-001 included a systematic analysis of the anti-CSC activity on in vitro and in vivo human-derived models of biologically aggressive, CSC-enriched types of human carcinomas.
Company Closed or Exit Year